Four clinical active surveillance trials including LORIS, COMET, LORD and LORETTA, are being conducted to assess whether women with low-risk ductal carcinoma in situ can safely avoid surgery. The present study aimed to determine the rate of upstaging to invasive cancer among patients with a preoperative diagnosis of ductal carcinoma in situ and to evaluate the incidence of upstaging in patients meeting the eligibility criteria for four active surveillance clinical trials.

中文翻译：

---

符合主动监测试验资格的患者的手术升级率

正在进行包括 LORIS、COMET、LORD 和 LORETTA 在内的四项临床主动监测试验，以评估患有低风险原位导管癌的女性是否可以安全地避免手术。本研究旨在确定术前诊断为原位导管癌的患者的浸润性癌升期率，并评估符合四项主动监测临床试验资格标准的患者的升期率。